Comparative Pharmacology
Head-to-head clinical analysis: AVYCAZ versus CEFAZOLIN AND DEXTROSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVYCAZ versus CEFAZOLIN AND DEXTROSE.
AVYCAZ vs CEFAZOLIN AND DEXTROSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVYCAZ is a combination of ceftazidime, a cephalosporin beta-lactam antibiotic, and avibactam, a non-beta-lactam beta-lactamase inhibitor. Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis. Avibactam protects ceftazidime from degradation by certain beta-lactamases, including Ambler class A, class C, and some class D enzymes.
Bactericidal agent inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis. Dextrose provides osmotic diuresis and energy source.
1 vial (ceftazidime 2g and avibactam 0.5g) IV over 2 hours every 8 hours.
1-2 g IV/IM every 8 hours; maximum 12 g/day.
None Documented
None Documented
Ceftazidime: ~2.8 hours; avibactam: ~2.7 hours. Extended in renal impairment (e.g., CrCl <50 mL/min requires dose adjustment).
1.8 hours (prolonged to 20-40 hours in severe renal impairment, CrCl <10 mL/min)
Ceftazidime: primarily renal (80-90% unchanged); avibactam: primarily renal (85-95% unchanged). Fecal excretion <1%.
Renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal (<5%)
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic